Home
HelpTest Code LAB2619 von Willebrand Factor Antigen, Plasma
Additional Codes
| Test Name in EPIC | EPIC Test Code | Mnemonic | Mayo Test ID |
|---|---|---|---|
| VON WILLEBRAND FACTOR AG | LAB2619 | VWAG | VWAG |
Reporting Name
von Willebrand Factor Ag, PUseful For
Diagnosis of von Willebrand disease (VWD) and differentiation of VWD subtype (in conjunction with von Willebrand factor ristocetin cofactor activity and factor VIII coagulant activity)
Differentiation of VWD from hemophilia A (in conjunction with factor VIII coagulant assay)
Monitoring therapeutic efficacy of treatment with DDAVP (desmopressin) or von Willebrand factor concentrates in patients with VWD
Method Name
Latex Immunoassay (LIA)
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Plasma Na CitOrdering Guidance
For optimum clinical utility and diagnostic efficiency, this test's results generally must be used together with the results of the von Willebrand factor ristocetin cofactor activity and factor VIII coagulant activity tests. The diagnosis of von Willebrand disease requires a combination of clinical and laboratory information. For a streamlined approach to testing, a panel of tests with reflexive testing and interpretive reporting is recommended. See AVWPR / von Willebrand Disease Profile, Plasma.
Additional Testing Requirements
VWACT / von Willebrand Factor Activity, Plasma and F8A / Coagulation Factor VIII Activity Assay, Plasma are recommended in conjunction with this test (von Willebrand antigen).
Specimen Required
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, less than or equal to -40° C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Special Instructions
Reference Values
55-200%
Note: Individuals of blood group "O" may have lower plasma von Willebrand factor (VWF) antigen than those of other ABO blood groups, such that apparently normal individuals of blood group "O" may have plasma VWF antigen as low as 40% to 50%, whereas the lower limit of the reference range for individuals of other blood groups may be 60% to 70%.
Children: Neonates, infants, and children have normal or mildly increased plasma VWF antigen, with respect to the adult reference range.
Day(s) Performed
Monday through Saturday
CPT Code Information
85246
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| VWAG | von Willebrand Factor Ag, P | 27816-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| VWAG | von Willebrand Factor Ag, P | 27816-8 |
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.Clinical Information
von Willebrand factor (VWF) is a multimeric adhesive glycoprotein that is important for platelet-platelet and platelet-vessel hemostatic interactions. In addition, plasma VWF serves as a carrier protein for coagulation factor VIII, stabilizing its procoagulant activity. VWF circulates in the blood in 2 distinct compartments; plasma VWF mainly reflects VWF synthesis and release from vascular endothelial cells and platelet VWF (about 10% of the blood VWF) reflects VWF synthesis by bone marrow megakaryocytes with storage primarily in the alpha granules of circulating platelets. VWF antigen measurement assesses the mass of plasma VWF protein but does not reflect VWF functions or platelet VWF. The major function of VWF (mediating platelet-platelet or platelet-vessel interaction) is most commonly assessed by measurement of plasma ristocetin cofactor activity.
Decreased VWF antigen may be seen in:
-Congenital von Willebrand disease
-Acquired von Willebrand disease that may be associated with monoclonal gammopathies, lymphoproliferative disorders, autoimmune disorders, and hypothyroidism
Increased VWF antigen may be seen in association with:
-Pregnancy and/or estrogen use
-Inflammation (acute-phase reactant)
-Exercise or stress
-Liver disease
-Vasculitis
-Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
Note: VWF antigen measurement is most effective when it is combined with measurement of VWF ristocetin cofactor activity and factor VIII coagulant activity, preferably as a panel of tests with reflexive testing and interpretive reporting. Within this context, VWF antigen measurement can be useful for:
-Diagnosis of von Willebrand disease (VWD) and differentiation of VWD subtype
-Differentiation of VWD from hemophilia A (in conjunction with factor VIII coagulant assay)
Interpretation
Patients with congenital severe type III von Willebrand disease (VWD) have a markedly decreased or undetectable level of von Willebrand factor (VWF) antigen in the plasma (and in the platelets), in addition to a plasma ristocetin cofactor activity that is either very low or not detectable.
Patients with types IIA and IIB variants of VWF (with abnormal plasma VWF function and multimeric structure) may have normal or decreased plasma VWF antigen. However, they typically have decreased plasma ristocetin cofactor activity, along with decreased higher molecular-weight VWF multimers in the plasma.
Patients with types IIM or IIN VWD have normal levels of VWF antigen. In spite of this, they either have decreased vWF ristocetin cofactor activity, not caused by absence of higher molecular weight vWF multimers (type IIM VWD), or decreased factor VIII coagulant activity (type IIN VWD)
Patients with type I VWD (with decreased but normally functioning plasma VWF) have concordantly decreased plasma VWF antigen and ristocetin cofactor activity.
Patients with acquired VWD may have either normal or decreased plasma VWF antigen.
Cautions
Lipemic specimens may lead to an underestimation of the von Willebrand factor (VWF) level.
The presence of rheumatoid factor may lead to an overestimation of the VWF level.
VWF is an acute-phase reactant and may be elevated above baseline in association with a variety of conditions including inflammation, stress, exercise, liver disease, pregnancy, or estrogen therapy. Baseline VWF levels also increase with aging. These conditions may obscure diagnosis of the milder forms of von Willebrand disease (VWD). Repeat testing may be indicated.
Low normal levels of VWF antigen do not exclude possible diagnosis of VWD.
Borderline low or slightly decreased levels of VWF antigen may be observed in clinically normal individuals of blood group "O."
Supportive Data
Mayo studies demonstrate excellent concordance between the enzyme-linked immunosorbent assay and this automated latex immunoassay (LIA) (r[2]=0.95) in about 80 patient specimens (with von Willebrand factor: VWF antigen ranging from 3% to 800%), and satisfactory concordance between VWF antigen by LIA and ristocetin cofactor activity (r[2]=0.88).
Method Description
This assay is performed using the HemosIL von Willebrand Factor Antigen kit on the Instrumentation Laboratory ACL TOP. This is a latex immunoassay method using microlatex particles coated with specific rabbit-polyclonal antibody directed against von Willebrand factor (VWF). In the presence of VWF antigen, antibody-coated latex particles agglutinate to form aggregates of diameters greater than the wavelength of the light passing through the sample and more light is absorbed as aggregation increases. The increase in absorption is proportional to the concentration of VWF antigen present in the sample.(Veyradier A, Fressinaud E, Sigaud M, et al. A new automated method for von Willebrand factor antigen measurement using latex particles. Thromb Haemost. 1999;81:320-321)
Report Available
1 to 3 daysSpecimen Retention Time
7 daysForms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.